SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

Summation

  • Although intra-operative neuro-navigation is commonplace in the operating room, the standard of care practiced in the intensive care unit and emergency room has changed very little in more than a century, and is entirely reliant on physicians' experience and knowledge of the brain's intricate anatomy.
  • “Early on in my career, I lost a patient I was caring for as a result of EVD complications,” said inTRAvent co-founder and Chief Medical Officer Dr.
  • “Throughout my career, I have watched neuro-navigation become the standard of care in neurosurgical operating rooms, while growing increasingly frustrated that in the ICU and at bedside, we are still performing brain procedures ‘free-hand,' using only surface landmarks,” added Dr.

SOLOPASS® system by inTRAvent Medical Partners LP, a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve neurosurgical procedures, today announced FDA 510(k) clearance for aiding in the frontal placement of intra-ventricular catheters.

SOLOPASS is designed to provide imaging and guidance to improve the placement of external ventricular drains (EVDs), one of the most common and lifesaving procedures occurring in neurointensive care.

Although intra-operative neuro-navigation is commonplace in the operating room, the standard of care practiced in the intensive care unit and emergency room has changed very little in more than a century, and is entirely reliant on physicians’ experience and knowledge of the brain’s intricate anatomy. In many cases, the intracranial anatomy is distorted, (a phenomenon known as “brain shift”), due to excess cerebrospinal fluid, traumatic brain injury, cerebral edema, and other conditions in which the pressure within the skull can reach dangerous levels. Without the aid of contemporary guidance technologies, these conditions make bedside EVD placement challenging – even for highly skilled practitioners.

SOLOPASS allows caregivers to visualize the ventricular system, deep within the brain, to enable precision planning and guidance. The system uses 2D and 3D ultrasound imaging, artificial intelligence, and trajectory guidance for intra-procedural localization and navigation. Imaging occurs at the point of procedure, eliminating the potential for brain shift that may affect the accuracy of conventional neuro-navigation systems.

“Early on in my career, I lost a patient I was caring for as a result of EVD complications,” said inTRAvent co-founder and Chief Medical Officer Dr. Will Hazard, who first conceptualized the technology. “Our aim has always been to advance the standard of care for this all-too-common, unsolved problem.”

“The technique for external ventricular drainage has not changed in 100 years. SOLOPASS is the first major advance in how we perform these invasive brain procedures. I believe it is potentially a game changer, particularly for patients with distorted anatomy,” said Dr. Aaron Cohen-Gadol, Professor of Neurological surgery and Director of Neuro-oncology at the Indiana University School of Medicine and founder and CEO of The Neurosurgical Atlas.

“Throughout my career, I have watched neuro-navigation become the standard of care in neurosurgical operating rooms, while growing increasingly frustrated that in the ICU and at bedside, we are still performing brain procedures ‘free-hand,’ using only surface landmarks,” added Dr. Michael Oh, Professor & Vice Chair of Education at the University of California, Irvine. “I’m confident that, by bringing neuro-navigation into these settings, we will expand the scope and breadth of neuro-critical care and provide our patients with better and earlier life-saving interventions.”

“There’s been an increasing focus on bettering patient outcomes while improving healthcare economics. SOLOPASS represents a significant advancement in the treatment of these critically ill patients, and we believe it can potentially reduce downstream healthcare costs associated with lengthy stays in the ICU,” said inTRAvent co-founder and CEO Adam Barner.

Other FDA News of Interest

FDA Grants AI-Powered Notal Vision Home OCT “SCANLY” De Novo Marketing Authorization

“We are very excited to receive FDA authorization to market SCANLY Home OCT as the first-ever patient self-operated, home-use device that gives physicians remote access to high-resolution, cross-sectional retinal images and AI-based analytical biomarkers of their patients eyes between office visits,” said Kester Nahen, PhD, CEO of Notal Vision. “We look forward to supporting our referring physicians in navigating their wet AMD patients’ care.”

Atraverse Medical Receives FDA Clearance for HOTWIRE™ Left Heart Access Device, Oversubscribes Seed Round with $12.5M Invested

The HOTWIRE system, invented by Atraverse Medical Co-Founders Dr. Steven Mickelsen and Eric Sauter, introduces a paradigm shift in left-heart access.

RapidAI Secures FDA Clearance for Perfusion Imaging in the Angiography Suite

“We are pleased to expand our stroke AI imaging portfolio, the broadest in the industry, to include this new module. With AngioFlow™ by RapidAI, we can now support stroke AI imaging along the entire patient pathway, from the initial non-contrast CT scan all the way to the interventional suite,” said Karim Karti, CEO of RapidAI. “Already registered and used in Japan and Europe, we believe this technology will make a significant difference in the lives of U.S. stroke patients.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy